The authors have nothing to acknowledge.

手順のすべてを見直し、忠南国立大学病院の治験審査委員会によって承認されました。 超音波検査1.測定<ol><li>患者の姿勢を設定します。 <ol><li>ベッドの上で両腕で、仰臥位で患者の腕を置きます。 </li></ol></li><li>患者の上肢の測定部位を決定。 <ol><li>手首のしわの中間点でマーク、内側および外側上顆肘のレベルで、ペンによって二頭筋溝の間の中間点。 </li><li>ペンを使用して直接定規ことにより、これらの3点を結びます。マーク上腕と前腕の2つの対象領域（ 図1）。 <ol><li>肘と二頭筋溝の間の線に沿ってエルボ点に近位部、10cmの近位をマークします。 </li><li>肘と手首の間の線に沿ってエルボ点に遠位部、10cmの先端をマークします。 </li></ol></li></ol></li><li>上肢の皮下組織および筋肉の厚さを測定します。手順は、熟練した検査技師が行ってください。 <ol><li>超音波システムのスイッチをオンにします。キーボードを介して、軟組織の2Dモードを入力します。 5センチメートルに深さを設定します。 <ol><li> 14L5リニアアレイトランスデューサを選択してください。 </li><li>超音波トランスデューサに十分なゲルを適用します。皮下組織に焦点を当てています。 </li></ol></li><li>上肢腹軸に対して垂直に超音波振動子を配置します。短軸ビューを使用します。ゲルの厚さが少なくとも1cmであると軟部組織の輪郭が歪んでいない画像をキャプチャします。 </li><li>筋肉や皮下組織の厚さを測定します。 <ol><li>超音波システムのキーボードを介しソフトウェアにキャリブレータを選択して線を描画します</li><li>最高点に骨の境界上の最高点からの距離として定義され、筋肉の厚さを測定筋膜の境界部分に（ 図2）。 </li><li>筋膜への皮膚からの距離として定義され、皮下組織の厚さを測定します。 </li></ol></li></ol></li></ol> BCRLへの超音波検査の2臨床応用<ol><li>ベースラインでの上肢の皮下組織および筋肉の厚さを測定します。 <ol><li>ステップ1に示すために、ベースライン測定を行います。 </li></ol></li><li> 0.5キロのダンベル14を使用してのPREのシリーズを実行するために患者に指示します。 <ol><li>着用する患者に圧迫ストッキングや多層包帯を与えます。 0.5キロのダンベルを選択してください。 </li><li>次の順序でのPREを実行するために患者に指示：（1）ダンベル、（2）三頭筋の拡張、（3）一方のアームベント・オーバー・ローイング、（4）上腕二頭筋カール、（5）ダンベルサイドレイズ、及びフライ（6 ）前方に腕を持ち上げる（ 図3）。 <ol><li> 6を完了するために患者に指示第1週の間に5回ずつ、2 回目の週の間に10回ずつ、3 回目の週の間に15回ずつ、4 週目の間に20回ずつ、25回：以下のスケジュールに従って演習一日二回、 5 番目の -8 番目の週（ 図4）中の各。 </li></ol></li></ol></li><li>従来の治療法に比べてPREの治療効果を識別するために超音波検査を使用してください。 <ol><li> 4および8週目に皮下組織と上肢の筋肉の厚さを測定します。ステップ1に示す順序で測定を行います。 </li></ol></li><li>ベースライン、4週目、および8週目の皮下組織および筋肉の厚さを計算します。 </li><li>データを分析します。 <ol><li>ペアリングトンの検定を用いて、両腕の間の差を比較してください。反復測定ANOVAを用いて、皮下組織や筋肉の厚さの変化を比較してください。 </li></ol></li></ol>

<ol>
	<li>Lasinski, B. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Complete+decongestive+therapy+for+treatment+of+lymphedema.">Complete decongestive therapy for treatment of lymphedema.</a> Seminars in Oncology Nursing. 29 (1), 20-27 (2013).</li><li>Clark, B., Sitzia, J., Harlow, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Incidence+and+risk+of+arm+oedema+following+treatment+for+breast+cancer:+a+three-year+follow-up+study.">Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study.</a> Q J Med. 98 (5), 343-348 (2005).</li><li>Hayes, S. C., Speck, R. M., Reimet, E., Stark, A., Schmitz, K. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Does+the+effect+of+weight+lifting+on+lymphedema+following+breast+cancer+differ+by+diagnostic+method:+results+from+a+randomized+controlled+trial.">Does the effect of weight lifting on lymphedema following breast cancer differ by diagnostic method: results from a randomized controlled trial.</a> Breast Cancer Res Treat. 130 (1), 227-234 (2011).</li><li>Fu, M. R., Ridner, S. H., Armer, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Post-breast+cancer+lymphedema:+part+1.">Post-breast cancer lymphedema: part 1.</a> Am J Nurs. 109 (7), 48-54 (2009).</li><li>Rockson, S. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ultrasonography+in+the+Evaluation+of+Breast+Cancer-Related+Lymphedema.">Ultrasonography in the Evaluation of Breast Cancer-Related Lymphedema.</a> Lymphatic Research and Biology. 14 (1), 1 (2016).</li><li>Suehiro, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Significance+of+Ultrasound+Examination+of+Skin+and+Subcutaneous+Tissue+in+Secondary+Lower+Extremity+Lymphedema.">Significance of Ultrasound Examination of Skin and Subcutaneous Tissue in Secondary Lower Extremity Lymphedema.</a> Ann Vasc Dis. 6 (2), 180-188 (2013).</li><li>Lee, J. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ultrasonographic+Evaluation+of+Therapeutic+Effects+of+Complex+Decongestive+Therapy+in+Breast+Cancer-Related+Lymphedema.">Ultrasonographic Evaluation of Therapeutic Effects of Complex Decongestive Therapy in Breast Cancer-Related Lymphedema.</a> Ann Rehabil Med. 37 (5), 683-689 (2013).</li><li>DiSipio, T., Rye, S., Newman, B., Hayes, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Incidence+of+unilateral+arm+lymphoedema+after+breast.">Incidence of unilateral arm lymphoedema after breast.</a> Lancet Oncol. 14 (6), 500-515 (2013).</li><li>Stanton, A. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymphatic+drainage+in+the+muscle+and+subcutis+of+the+arm+after+breast+cancer+treatment.">Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment.</a> Breast Cancer Res Treat. 117 (3), 549-557 (2008).</li><li>Godoy, M. F. G., Pereira, M. R., Oliani, A. H., Godoy, J. M. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synergic+Effect+of+Compression+Therapy+and+Controlled+Active+Exercises+Using+a+Facilitating+Device+in+the+Treatment+of+Arm+Lymphedema.">Synergic Effect of Compression Therapy and Controlled Active Exercises Using a Facilitating Device in the Treatment of Arm Lymphedema.</a> Int J Med Sci. 9 (4), 280-284 (2012).</li><li>Cormie, P., Pumpa, K., Galv&#227;o, D. A., Turner, E., Spry, N., Saunders, C., Zissiadis, Y., Newton, R. U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Is+it+safe+and+efficacious+for+women+with+lymphedema+secondary+to+breast+cancer+to+lift+heavy+weights+during+exercise:+a+randomised+controlled+trial.">Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial.</a> J Cancer Surviv. 7 (3), 413-424 (2013).</li><li>Bok, S. K., Jeon, Y., Hwang, P. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ultrasonographic+evaluation+of+the+effects+of+progressive+resistive+exercise+in+breast+cancer-related+lymphedema.">Ultrasonographic evaluation of the effects of progressive resistive exercise in breast cancer-related lymphedema.</a> Lymphatic Research and Biology. 14 (1), 18-24 (2016).</li><li>Milne, H. M., Wallman, K. E., Gordon, S., Courneya, K. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effects+of+a+combined+aerobic+and+resistance+exercise+program+in+breast+cancer+survivors:+a+randomized+controlled+trial.">Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial.</a> Breast Cancer Res Treat. 108 (2), 279-288 (2008).</li><li>Schmitz, K. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Weight+lifting+for+women+at+risk+for+breast-cancer-related+lymphedema.">Weight lifting for women at risk for breast-cancer-related lymphedema.</a> JAMA. 304 (24), 2699-2705 (2010).</li><li>Kiel, K. D., Rademacker, A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early-stage+breast+cancer:+Arm+edema+after+wide+excision+and+breast+irradiation.">Early-stage breast cancer: Arm edema after wide excision and breast irradiation.</a> Radiology. (1), 279-283 (1996).</li></ol>

The authors have nothing to disclose.

BCRLの評価は、腕周テープ測定、水の変位測定、生体インピーダンス分光法、perometry（光電子容積）、リンパシンチグラフィ、臨床医の診断、または患者による自己報告膨潤を含む様々な技術によって行うことができます。しかし、BCRLの測定のための基準はありません。治療の診断および持続時間は、診療所に応じて、いくつかの方法で経験的に決定することができます。 <p class="jove_conte...

リンパ浮腫は妥協リンパ系1,2による膨れ局在するタンパク質が豊富な体液貯留や組織の状態として定義されています。リンパ浮腫が進行するにつれて、線維細胞および/または脂肪細胞は、皮膚と皮下組織および細菌や真菌感染3,4に増加した脆弱性のテクスチャーの変化につながる、被災地で増殖します。四肢の様々な部分におけるこれらの変化の観察は、さらに重症度とリンパ浮腫の程度を解明することができます。筋膜下リンパ系は、筋膜上のリンパ系よりもリンパ浮腫の重症度に貢献しています。 最近の研究では、主にリンパ浮腫5,6の診断における超音波検査の使用に焦点を当てています。超音波検査は、軟部組織の特性を観察する比較的安価な方法です。以前の研究では、リンパ浮腫を確実Tを比較することにより、超音波を用いて診断することができることを報告し彼は、臨床設定7,8における皮下組織のコンプライアンスを評価することにより、皮膚と皮下組織の厚さと。また、超音波検査が広く、その簡単にアクセス、放射線被曝からの安全性、および安価5,6の診療所で使用されています。これらの利点にもかかわらず、リンパ浮腫のための超音波検査の研究だけではない治療的介入の評価に、診断に焦点が当てられてきました。 したがって、現在の研究では、BCRL上のPREの影響を解明における超音波検査の有用性だけでなく、を決定することを目的とした、だけでなく、超音波検査、治療の有効性を確認するには、フォローアップテストとして臨床的意義を持っているかどうか。この研究は、リンパ浮腫を調べるために行う超音波のためのプロトコルを確立するために行きました。

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>ACUSON S2000</td>
			<td>Siemens</td>
			<td>10041461</td>
			<td></td>
		</tr>
		<tr>
			<td>Eco Gel 99</td>
			<td>Seung Won Medical Corp.</td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

ultrasonographic evaluation of breast cancer-related lymphedema

リンパ浮腫は、乳癌手術後の最も一般的な合併症の1つです。そこリンパ浮腫のための多くの診断ツールがありますが、標準的な方法がまだ存在しません。プログレッシブレジスタンス運動（PRE）は、追加の腫脹なしでリンパ浮腫を改善することが期待されます。この研究は、筋肉及び皮下組織の厚さの変化を測定するために超音波を使用して、リンパ浮腫のPREの治療効果を示しました。皮下組織の厚さは、非PRE群よりもPRE群でより減少しました。超音波検査は、その簡単にアクセス、安全性、および安価で多くの診療所で広く使用されています。 超音波は、診断および乳癌関連リンパ浮腫（BCRL）の治療効果を判定するための最高のツールの一つです。

この研究は、BCRLと診断された32人の患者が含まれていました。筋肉や皮下組織と近位および遠位上肢の周囲の厚さは、ベースライン、4週、およびPRE後8週目に測定しました。審査官は、巻尺で上肢の円周を測定し、その後、筋肉や皮下組織の厚さは、超音波検査で測定しました。患者を無作為PRE基および非PRE群に分けました。参加者は、測定および評価セッションの?...

Watch this Scientific Journal Video about Ultrasonographic Evaluation of Breast Cancer-related Lymphedema at JoVE.com

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

本研究では、診断用超音波を利用し、フォローアップ乳がん関連リンパ浮腫（BCRL）に漸増抵抗運動（PRE）の治療の有効性を確認するためのテストを。超音波検査は、リンパ浮腫の診断および治療を確実にするために効果的に適用することができます。

乳がん関連リンパ浮腫の超音波評価

Lymphedema is one of the most common complications after breast cancer surgery. There are many diagnostic tools for lymphedema, but no standard method yet ...

ultrasonographic-evaluation-of-breast-cancer-related-lymphedema

Research

JoVE Journal

Cancer Research

9.1K ビュー.  Chungnam National University Hospital (CNUH). 本研究では、診断用超音波を利用し、フォローアップ乳がん関連リンパ浮腫（BCRL）に漸増抵抗運動（PRE）の治療の有効性を確認するためのテストを。超音波検査は、リンパ浮腫の診断および治療を確実にするために効果的に適用することができます。 

ビデオ: Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the efficacy of novel therapies that make the transition from pre-clinical models to clinical trials.
Here we present a methodology for generating uniform and reproducible tumor spheroids that can be subjected to siRNA functional screening. These spheroids display many characteristics that are found in solid tumors that are not present in traditional two-dimension culture. We show that several commonly used breast cancer cell lines are amenable to this protocol. Furthermore, we provide proof-of-principle data utilizing the breast cancer cell line BT474, confirming their dependency on amplification of the epidermal growth factor receptor HER2 and mutation of phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) when grown as tumor spheroids. Finally, we are able to further investigate and confirm the spatial impact of these dependencies using immunohistochemistry.

Identifying novel drug targets that transition from pre-clinical testing to human trials is a scientific priority. To that end, here we describe a functional genomics approach for examining the impact of gene depletion on cancer cell line spheroids, which more appropriately model human cancers in vivo.

癌細胞スフェロイド培養における潜在的に新規薬剤標的を同定するためのスクリーニング機能ゲノミクスを利用

The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery ...

がん研究

Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish

In many cases, cancer patients do not die of a primary tumor, but rather because of metastasis. Although numerous rodent models are available for studying cancer metastasis in vivo, other efficient, reliable, low-cost models are needed to quickly access the potential effects of (epi)genetic changes or pharmacological compounds. As such, we illustrate and explain the feasibility of xenograft models using human breast cancer cells injected into zebrafish embryos to support this goal. Under the microscope, fluorescent proteins or chemically labeled human breast cancer cells are transplanted into transgenic zebrafish embryos, Tg (fli:EGFP), at the perivitelline space or duct of Cuvier (Doc) 48 h after fertilization. Shortly afterwards, the temporal-spatial process of cancer cell invasion, dissemination, and metastasis in the living fish body is visualized under a fluorescent microscope. The models using different injection sites, i.e., perivitelline space or Doc are complementary to one another, reflecting the early stage (intravasation step) and late stage (extravasation step) of the multistep metastatic cascade of events. Moreover, peritumoral and intratumoral angiogenesis can be observed with the injection into the perivitelline space. The entire experimental period is no more than 8 days. These two models combine cell labeling, micro-transplantation, and fluorescence imaging techniques, enabling the rapid evaluation of cancer metastasis in response to genetic and pharmacological manipulations.

Here, we describe xenograft zebrafish models using two different injection sites, i.e., perivitelline space and duct of Cuvier, to investigate the invasive behavior and to assess the intravasation and extravasation potential of human breast cancer cells, respectively.

胚ゼブラフィッシュにおけるヒト乳癌細胞の浸潤挙動

In many cases, cancer patients do not die of a primary tumor, but rather because of metastasis. Although numerous rodent models are available for studying ...

Live-imaging of Breast Epithelial Cell Migration After the Transient Depletion of TIP60

The wound-healing assay is efficient and one of the most economical ways to study cell migration in vitro. Conventionally, images are taken at the beginning and end of an experiment using a phase-contrast microscope, and the migration abilities of cells are evaluated by the closure of wounds. However, cell movement is a dynamic phenomenon, and a conventional method does not allow for tracking single-cell movement. To improve current wound-healing assays, we use live-cell imaging techniques to monitor cell migration in real time. This method allows us to determine the cell migration rate based on a cell tracking system and provides a clearer distinction between cell migration and cell proliferation. Here, we demonstrate the use of live-cell imaging in wound-healing assays to study the different migration abilities of breast epithelial cells influenced by the presence of TIP60. As cell motility is highly dynamic, our method provides more insights into the processes of wound healing than a snapshot of wound closure taken with the traditional imaging techniques used for wound-healing assays.

Here, we present the real-time monitoring of cell migration in a wound-healing assay using TIP60-depleted MCF10A breast epithelial cells. The implementation of live-cell imaging techniques in our protocol allows us to analyze and visualize single-cell movement in real time and across time.

乳腺上皮細胞移行 TIP60 の一時的な枯渇後のライブ イメージング

The wound-healing assay is efficient and one of the most economical ways to study cell migration in vitro. Conventionally, images are taken at the ...

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Fatigue is a common and debilitating condition that affects most cancer patients. To date, fatigue remains poorly characterized with no diagnostic test to objectively measure the severity of this condition. Here we describe an optimized method for assessing mitochondrial function of PBMCs collected from fatigued cancer patients. Using a compact extracellular flux system and sequential injection of respiratory inhibitors, we examined PBMC mitochondrial functional status by measuring basal mitochondrial respiration, spare respiratory capacity, and energy phenotype, which describes the preferred energy pathway to respond to stress. Fresh PBMCs are readily available in the clinical setting using standard phlebotomy. The entire assay described in this protocol can be completed in less than 4 hours without the involvement of complex biochemical techniques. Additionally, we describe a normalization method that is necessary for obtaining reproducible data. The simple procedure and normalization methods presented allow for repeated sample collection from the same patient and generation of reproducible data that can be compared between time points to evaluate potential treatment effects.

Our goal was to develop a practical protocol to evaluate mitochondrial dysfunction associated with fatigue in cancer patients. This innovative protocol is optimized for clinical use involving only standard phlebotomy and basic laboratory procedures.

がんに関連した疲労におけるミトコンドリア機能の役割の評価

Fatigue is a common and debilitating condition that affects most cancer patients. To date, fatigue remains poorly characterized with no diagnostic test to ...

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Acquired resistance to molecular target inhibitors is a severe problem in cancer therapy. Lung cancer remains the leading cause of cancer-related death in most countries. The discovery of "oncogenic driver mutations," such as epidermal growth factor receptor (EGFR)-activating mutations, and subsequent development of molecular targeted agents of EGFR tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) have dramatically altered lung cancer treatment in recent decades. However, these drugs are still not effective in patients with non-small cell lung cancer (NSCLC) carrying EGFR-activating mutations. Following acquired resistance, the systemic progression of NSCLC remains a significant obstacle in treating patients with EGFR mutation-positive NSCLC. Here, we present a stepwise dose escalation method for establishing three independent acquired afatinib-resistant cell lines from NSCLC PC-9 cells harboring EGFR-activating mutations of 15-base pair deletions in EGFR exon 19. Methods for characterizing the three independent afatinib-resistance cell lines are briefly presented. The acquired resistance mechanisms to EGFR TKIs are heterogeneous. Therefore, multiple cell lines with acquired resistance to EGFR-TKIs must be examined. Ten to twelve months are required to obtain cell lines with acquired resistance using this stepwise dose escalation approach. The discovery of novel acquired resistance mechanisms will contribute to the development of more effective and safe therapeutic strategies.

A method for establishing afatinib-resistance cell lines from lung adenocarcinoma PC-9 cells was developed, and resistant cells were characterized. The resistant cells can be used to investigate epidermal growth factor receptor tyrosine kinase inhibitor-resistance mechanisms, applicable for patients with non-small cell lung cancer.

アファチニブ耐性肺腺癌PC-9細胞株の確立と特徴付けは、アファチニブの用量の増加とともに開発された

Acquired resistance to molecular target inhibitors is a severe problem in cancer therapy. Lung cancer remains the leading cause of cancer-related death in ...

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Cadherins play an important role in the regulation of cell differentiation as well as neoplasia. Here we describe the origins and methods of the induction of differentiation of two mouse breast epithelial cell lines, HC11 and EpH4, and their use to study complementary stages of mammary gland development and neoplastic transformation.
The HC11 mouse breast epithelial cell line originated from the mammary gland of a pregnant Balb/c mouse. It differentiates when grown to confluence attached to a plastic Petri dish surface in medium containing fetal calf serum and Hydrocortisone, Insulin and Prolactin (HIP medium). Under these conditions, HC11 cells produce the milk proteins &#946;-casein and whey acidic protein (WAP), similar to lactating mammary epithelial cells, and form rudimentary mammary gland-like structures termed &#34;domes&#34;.
The EpH4 cell line was derived from spontaneously immortalized mouse mammary gland epithelial cells isolated from a pregnant Balb/c mouse. Unlike HC11, EpH4 cells can fully differentiate into spheroids (also called mammospheres) when cultured under three-dimensional (3D) growth conditions in HIP medium. Cells are trypsinized, suspended in a 20% matrix consisting of a mixture of extracellular matrix proteins produced by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, plated on top of a layer of concentrated matrix coating a plastic Petri dish or multiwell plate, and covered with a layer of 10% matrix-containing HIP medium. Under these conditions, EpH4 cells form hollow spheroids that exhibit apical-basal polarity, a hollow lumen, and produce &#946;-casein and WAP.
Using these techniques, our results demonstrated that the intensity of the cadherin/Rac signal is critical for the differentiation of HC11 cells. While Rac1 is necessary for differentiation and low levels of activated RacV12 increase differentiation, high RacV12 levels block differentiation while inducing neoplasia. In contrast, EpH4 cells represent an earlier stage in mammary epithelial differentiation, which is inhibited by even low levels of RacV12.

We describe techniques for differentiation induction of two breast epithelial lines, HC11 and EpH4. While both require fetal calf serum, insulin, and prolactin to produce milk proteins, EpH4 cells can fully differentiate into mammospheres in three-dimensional culture. These complementary models are useful for signal transduction studies of differentiation and neoplasia.

マウス乳房上皮HC11細胞とEpH4細胞の分化

Cadherins play an important role in the regulation of cell differentiation as well as neoplasia. Here we describe the origins and methods of the induction ...

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. When compared to patients with less aggressive breast tumors, the 5-year survival rate of TNBC patients is 77% due to their characteristic drug-resistant phenotype and metastatic burden. Toward this end, murine models have been established aimed at identifying novel therapeutic strategies limiting TNBC tumor growth and metastatic spread. This work describes a practical guide for the TNBC orthotopic model where MDA-MB-231 breast cancer cells suspended in a basement membrane matrix are implanted in the fourth mammary fat pad, which closely mimics the cancer cell behavior in humans. Measurement of tumors by caliper, lung metastasis assessment via in vivo and ex vivo imaging, and molecular detection are discussed. This model provides an excellent platform to study therapeutic efficacy and is especially suitable for the study of the interaction between the primary tumor and distal metastatic sites.

This work presets an advanced protocol to accurately assess tumor loading by detection of green fluorescent protein and bioluminescence signals as well as the integration of quantitative molecular detection technique.

交感性乳癌モデルを用いたトリプルネガティブ乳癌の研究

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. When compared to patients with less ...

Measuring the Motor Aspect of Cancer-Related Fatigue using a Handheld Dynamometer

Cancer-related fatigue (CRF) is commonly reported by patients both during and after receiving treatment for cancer. Current CRF diagnoses rely on self-report questionnaires which are subject to report and recall biases. Objective measurements using a handheld dynamometer, or handgrip device, have been shown in recent studies to correlate significantly with subjective self-reported fatigue scores. However, variations of both the handgrip fatigue test and fatigue index calculations exist in the literature. The lack of standardized methods limits the utilization of the handgrip fatigue test in the clinical and research settings. In this study, we provide detailed methods for administering the physical fatigue test and calculating the fatigue index. These methods should supplement existing self-reported fatigue questionnaires and help clinicians assess fatigue symptom severity in an objective and quantitative manner.

Simple and accessible methods were developed to measure the motor aspect of cancer-related fatigue objectively and quantitatively. We describe, in detail, ways to administer the physical fatigue test using a simple handgrip device as well as methods to calculate fatigue indices.

ハンドヘルドダイナモメーターを用いた癌関連疲労の運動面の測定

Cancer-related fatigue (CRF) is commonly reported by patients both during and after receiving treatment for cancer. Current CRF diagnoses rely on ...

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Preclinical models that faithfully recapitulate tumor heterogeneity and therapeutic response are critical for translational breast cancer research. Immortalized cell lines are easy to grow and genetically modify to study molecular mechanisms, yet the selective pressure from cell culture often leads to genetic and epigenetic alterations over time. Patient-derived xenograft (PDX) models faithfully recapitulate the heterogeneity and drug response of human breast tumors. PDX models exhibit a relatively short latency after orthotopic transplantation that facilitates the investigation of breast tumor biology and drug response. The transplantable genetically engineered mouse models allow the study of breast tumor immunity. The current protocol describes the method to orthotopically transplant breast tumor fragments into the mammary fat pad followed by drug treatments. These preclinical models provide valuable approaches to investigate breast tumor biology, drug response, biomarker discovery and mechanisms of drug resistance.

Patient-derived xenograft (PDX) models and transplantable genetically engineered mouse models faithfully recapitulate human disease and are preferred models for basic and translational breast cancer research. Here, a method is described to orthotopically transplant breast tumor fragments into the mammary fat pad to study tumor biology and evaluate drug response.

乳癌の前臨床モデルとしての乳房腫瘍の移植性

Preclinical models that faithfully recapitulate tumor heterogeneity and therapeutic response are critical for translational breast cancer research. ...

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Breast cancer (BC) remains a leading cause of death for women. Despite more than $700 million invested in BC research annually, 97% of candidate BC drugs fail clinical trials. Therefore, new models are needed to improve our understanding of the disease. The NIH Microphysiological Systems (MPS) program was developed to improve the clinical translation of basic science discoveries and promising new therapeutic strategies. Here we present a method for generating MPS for breast cancers (BC-MPS). This model adapts a previously described approach of culturing primary human white adipose tissue (WAT) by sandwiching WAT between adipose-derived stem cell sheets (ASC)s. Novel aspects of our BC-MPS include seeding BC cells into non-diseased human breast tissue (HBT) containing native extracellular matrix, mature adipocytes, resident fibroblasts, and immune cells; and sandwiching the BC-HBT admixture between HBT-derived ASC sheets. The resulting BC-MPS is stable in culture ex vivo for at least 14 days. This model system contains multiple elements of the microenvironment that influence BC including adipocytes, stromal cells, immune cells, and the extracellular matrix. Thus BC-MPS can be used to study the interactions between BC and its microenvironment. 
We demonstrate the advantages of our BC-MPS by studying two BC behaviors known to influence cancer progression and metastasis: 1) BC motility and 2) BC-HBT metabolic crosstalk. While BC motility has previously been demonstrated using intravital imaging, BC-MPS allows for high-resolution time-lapse imaging using fluorescence microscopy over several days. Furthermore, while metabolic crosstalk was previously demonstrated using BC cells and murine pre-adipocytes differentiated into immature adipocytes, our BC-MPS model is the first system to demonstrate this crosstalk between primary human mammary adipocytes and BC cells in vitro.

This protocol describes the construction of an in vitro microphysiological system for studying breast cancer using primary human breast tissue with off the shelf materials.

微小生理学的システムを用いたヒト乳房組織における乳癌のモデル化

Breast cancer (BC) remains a leading cause of death for women. Despite more than $700 million invested in BC research annually, 97% of candidate BC drugs ...

乳がん関連リンパ浮腫の超音波評価

要約

さらに動画を探す

この動画の章

癌細胞スフェロイド培養における潜在的に新規薬剤標的を同定するためのスクリーニング機能ゲノミクスを利用

胚ゼブラフィッシュにおけるヒト乳癌細胞の浸潤挙動

乳腺上皮細胞移行 TIP60 の一時的な枯渇後のライブイメージング

がんに関連した疲労におけるミトコンドリア機能の役割の評価

アファチニブ耐性肺腺癌PC-9細胞株の確立と特徴付けは、アファチニブの用量の増加とともに開発された

マウス乳房上皮HC11細胞とEpH4細胞の分化

交感性乳癌モデルを用いたトリプルネガティブ乳癌の研究

ハンドヘルドダイナモメーターを用いた癌関連疲労の運動面の測定

乳癌の前臨床モデルとしての乳房腫瘍の移植性

微小生理学的システムを用いたヒト乳房組織における乳癌のモデル化

乳がん関連リンパ浮腫の超音波評価

要約

さらに動画を探す

この動画の章

癌細胞スフェロイド培養における潜在的に新規薬剤標的を同定するためのスクリーニング機能ゲノミクスを利用

胚ゼブラフィッシュにおけるヒト乳癌細胞の浸潤挙動

乳腺上皮細胞移行 TIP60 の一時的な枯渇後のライブ イメージング

がんに関連した疲労におけるミトコンドリア機能の役割の評価

アファチニブ耐性肺腺癌PC-9細胞株の確立と特徴付けは、アファチニブの用量の増加とともに開発された

マウス乳房上皮HC11細胞とEpH4細胞の分化

交感性乳癌モデルを用いたトリプルネガティブ乳癌の研究

ハンドヘルドダイナモメーターを用いた癌関連疲労の運動面の測定

乳癌の前臨床モデルとしての乳房腫瘍の移植性

微小生理学的システムを用いたヒト乳房組織における乳癌のモデル化

乳腺上皮細胞移行 TIP60 の一時的な枯渇後のライブイメージング